114 related articles for article (PubMed ID: 17150261)
21. Synthesis and characterization of cytidine derivatives that inhibit the kinase IspE of the non-mevalonate pathway for isoprenoid biosynthesis.
Crane CM; Hirsch AK; Alphey MS; Sgraja T; Lauw S; Illarionova V; Rohdich F; Eisenreich W; Hunter WN; Bacher A; Diederich F
ChemMedChem; 2008 Jan; 3(1):91-101. PubMed ID: 18033714
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
23. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.
Furlong SJ; Ridgway ND; Hoskin DW
Int J Oncol; 2008 Mar; 32(3):537-44. PubMed ID: 18292930
[TBL] [Abstract][Full Text] [Related]
24. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
25. Src continues aging: current and future clinical directions.
Kopetz S; Shah AN; Gallick GE
Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Endocr Relat Cancer; 2007 Sep; 14(3):839-45. PubMed ID: 17914112
[TBL] [Abstract][Full Text] [Related]
27. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
Kazuno H; Fujioka A; Fukushima M; Wataya Y; Matsuda A; Sasaki T
Int J Oncol; 2009 May; 34(5):1373-80. PubMed ID: 19360349
[TBL] [Abstract][Full Text] [Related]
28. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
29. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
30. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
Hu X; Xuan Y
Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
[TBL] [Abstract][Full Text] [Related]
31. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
Wiemer AJ; Yu JS; Shull LW; Barney RJ; Wasko BM; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Apr; 16(7):3652-60. PubMed ID: 18308574
[TBL] [Abstract][Full Text] [Related]
32. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitors in multiple myeloma.
Anderson KC
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
35. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
36. The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Wiemer AJ; Hohl RJ; Wiemer DF
Anticancer Agents Med Chem; 2009 Jun; 9(5):526-42. PubMed ID: 19519294
[TBL] [Abstract][Full Text] [Related]
37. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
38. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Egler V; Korur S; Failly M; Boulay JL; Imber R; Lino MM; Merlo A
Clin Cancer Res; 2008 May; 14(10):3132-40. PubMed ID: 18483381
[TBL] [Abstract][Full Text] [Related]
40. Drug interactions between chemotherapeutic regimens and antiepileptics.
Yap KY; Chui WK; Chan A
Clin Ther; 2008 Aug; 30(8):1385-407. PubMed ID: 18803983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
